Approval of the selective inhibitor of BCR–ABL1 kinase activity, imatinib mesylate (Gleevec, Glivec, STI571), has commemorated the beginning of a new era of anticancer targeted medicine in the treatment of BCR–ABL1-positive leukemias [156]. The gene discussed is ABL1; the disease is leukemia.